/
SCNI
$0.27+$0.02 (+7.17%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.3M
5M shares
52-week range
$0.24 – $3.48
1% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
ADRC
Borrow rate
106.03%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-13.03
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $658.0K | $1.3M |
| Cost of revenue | $72.3K | $461.7K | $708.9K | $747.6K | $559.8K | $512.7K | $1.2M | $4.0M |
| Gross profit | $0 | $0 | −$708.9K | −$747.6K | −$559.8K | −$512.7K | −$580.0K | −$2.7M |
| Gross margin | — | — | — | — | — | — | -88.1% | -202.3% |
| R&D | $19.3M | $19.9M | $16.0M | $3.2M | $5.8M | $5.2M | $5.5M | $2.4M |
| Operating income | −$20.6M | −$22.7M | $2.3M | −$10.9M | −$11.1M | −$9.7M | −$8.6M | −$7.5M |
| EBITDA | −$20.5M | −$22.2M | $2.8M | −$10.4M | −$10.5M | −$9.2M | −$7.0M | −$6.5M |
| Net income | −$23.5M | −$31.6M | −$1.4M | −$8.2M | −$5.8M | −$6.5M | $4.8M | −$8.3M |
| Net margin | — | — | — | — | — | — | 728.9% | -633.6% |
| EPS (diluted) | -1435800.00 | -1548800.00 | -12.40 | -80.00 | -30.80 | -16.80 | 6.00 | -3.60 |
Annual figures · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$10.17
Price
$0.27
Implied upside
+3680%
Peer comparison
Scinai Immunotherapeutics Ltd. American Depositary Shares
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
www.scinai.com- Employees
- 45
- IPO / List date
- May 12, 2015
- HQ
- JERUSALEM, L3
Held by traders on TradeandTell
No one on the platform currently holds SCNI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in SCNI as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-05-21 | 1-for-10reverse |
| 2022-11-25 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded SCNI yet.
